Who is sponsoring NCT03387501?

NCT03387501 is sponsored by Sara Rafael Fernandez.

What drugs are being tested in NCT03387501?

Interventions in NCT03387501: Plasma rich in growth factors (PRGF-Endoret).

What condition does NCT03387501 study?

NCT03387501 studies Infertility, Infertility, Female.

Is NCT03387501 still recruiting?

NCT03387501 is currently completed. Last updated 8 September 2022.

Last reviewed 2022-09-08 · How we verify

NCT03387501: APTE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

Completed Phase 2 Last updated 8 September 2022

What this trial tests

Phase 2 trial testing Plasma rich in growth factors (PRGF-Endoret) in Infertility in 13 participants. Completed in 26 July 2022.

Timeline

27 May 2019

Primary endpoint
26 July 2022

26 July 2022

Quick facts

Lead sponsor	Sara Rafael Fernandez
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	27 May 2019
Primary completion	26 July 2022
Estimated completion	26 July 2022
Sites	1 location across Spain

Drugs / interventions tested

Plasma rich in growth factors (PRGF-Endoret) — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →
Infertility, Female — all drugs for Infertility, Female →

Sponsor

Sara Rafael Fernandez

Who can join

Adults 18 to 40, female only, with Infertility or Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Plasma rich in growth factors (PRGF-Endoret)

Trials testing the same drug.

NCT06664268 — Effect of PRF & Fractional CO2 Laser in Postburn Hypertrophic Scars · EARLY_PHASE1 · not yet recruiting

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03387501 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sara Rafael Fernandez
Last refreshed: 8 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03387501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing